ChemoCentryx and the Vifor Pharma Group this morning announced their decision to withdrawal the Conditional Marketing Authorization application for avacopan for the treatment of ANCA-associated vasculitis. H.C. Wainwright analyst Edward White viewed the possible CMA approval as a potential upside for shares of ChemoCentryx but did not incorporate it into his models. He continues to anticipate a New Drug Applicaton filing with the FDA in the first half of 2020 and projects revenues of $72M for avacopan in AAV in 2021, growing to $1.4B in 2028. As such, White is making no changes to his estimates or $20 price target following the news and keeps a Buy rating on ChemoCentryx. The stock in morning trading is down 28c to $11.48.